Microbot Medical is the end of Investing.com’s clinical trial

BRAINTREE, Mass. – Microbot Medical Inc. (NASDAQ:MBOT), a clinical-stage medical technology, compound fortschritte in the ACCESS-PVI trial for the LIBERTY® Endovascular Robotic Surgery System. The study is a described patient recruitment, of which 80% of the treatment phase deviates from the treatment. This Entwicklung puts education on the right track, the study can manifest itself if something goes wrong.

The ACCESS-PVI study, a progressive, multicentre Single Arm study, is the Leistung en Sicherheit of the LIBERTY® systems in peripheral vascular interventions possible. The positive treatment of patient recruitment begins with the treatment of the medical world, until the end of 2024 a 510(k)-Antrag with the US FDA application.

Harel Gadot, former chairman of the network, CEO and chairman of Microbot Medical, said he went into the study with the research and there was a point where the FDA application was approved. This is the Medical Leader Juan Diaz-Cartelle who has determined the involvement of Microbot Teams and the Teilnehmenden.

Clinical trials of Microbot Medical have been completed for the Investigational Device Exemption (IDE)-Antragic Erforderlichen biocompatibility testing and final IDE approval from the FDA.

The LIBERTY® Endovascular Robotic Surgery System is a micro-robotic technology that makes it possible to revolutionize endovascular procedures. The elimination of the Notnauwkeit greater Geräte, reduces the Strahlentaxung and reduces the Tax for the Arzt. The fermentation function of the systems is an endovascular intervention that democratizes.

If you perform a laboratory test, it will be used in the 510(k)-Antrag einfließen. These studies are based on a press conference from Microbot Medical.

In others, Microbot Medical’s active functions involve performing active activities. The companies have developed a Phase 2 collaboration with Corewell Health with the further development of LIBERTY Endovaskulären Robotersystems for tele-surgery, after which Phase 1 will be completed. Microbot Medical is a segregated clinical trial on the LIBERTY System following FDA approval at Baptist Hospital of Miami.

Microbot Medical has done its best to use At-the-Market-Offering-Vereinbarung with HC Wainwright & Co., LLC, will offer and sell a trunk machine with a gesamtangebotpreis of an amount of 4,819,905 US-Dollar. Please note that the purchase price is 2.35 Million US Dollars and the purchase price for a purchase and investment option, sold by HC Wainwright & Co. functioned as exclusive Platzierungsagent.

HC Wainwright applied for Microbot Medical and paid a price for 7.00 US dollars, given the Kaufempfehlung at. Proud of the young Spaniards in Israel is the best Microbot Medical, which expands its active plan and sees another regulatory company, one of the LIBERTY system for the market introduction in the US and Europe to position. There are more and more studies for Microbot Medical.

InvestingPro Insights

Während Microbot Medical Inc. (NASDAQ:MBOT) with the ACCESS-PVI study conducted provided some important financial knowledge and experience with InvestingPro research. The market capitalization of the Unternehmens had a modest value of 14.21 million US dollars, was more widely mirrored as a status of medical technology in the clinical phase.

InvestPro data says that Microbot Medical’s action is trading at age 52, but 36.64% of 52-wochen-hochs relations. If you are a value investor of interest, explore the strong development in the clinical trial of internal medicine. Once you get to the beach, the year that saw the market trending -47.49% is one of the volatile developments in the past.

Two relevant InvestingPro Tips have you said that Microbot Medical has more money as debt in its balance sheet and its liquid assets that have the latest enlightening effects. These factories can increase the university’s financial flexibility, making it an absolutely clinical trial and FDA application.

The fact is that InvestingPro offers 8 different tips for Microbot Medical, which even more emails for investors, who find an in-depth analysis of the financing of the economy and the market position of the internal market interesting.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.